{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,20]],"date-time":"2025-06-20T04:07:48Z","timestamp":1750392468922,"version":"3.41.0"},"reference-count":59,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Rheumatic Disease Clinics of North America"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1016\/j.rdc.2025.01.010","type":"journal-article","created":{"date-parts":[[2025,4,15]],"date-time":"2025-04-15T22:14:53Z","timestamp":1744755293000},"page":"383-395","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Newer Immunosuppressants for Rheumatologic Disease"],"prefix":"10.1016","volume":"51","author":[{"given":"Ye Rin","family":"Koh","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"suffix":"III","given":"Kenneth C.","family":"Cummings","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.rdc.2025.01.010_bib1","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1002\/art.10998","article-title":"Declining use of orthopedic surgery in patients with rheumatoid arthritis? Results of a long-term, population-based assessment","volume":"49","author":"Da Silva","year":"2003","journal-title":"Arthritis Care Res"},{"issue":"6","key":"10.1016\/j.rdc.2025.01.010_bib2","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1016\/j.arth.2019.02.018","article-title":"Inflammatory Arthritis Is a Risk Factor for Multiple Complications After Total Hip Arthroplasty: A Population-Based Comparative Study of 68,348 Patients","volume":"34","author":"Richardson","year":"2019","journal-title":"J\u00a0arthroplasty"},{"issue":"2","key":"10.1016\/j.rdc.2025.01.010_bib3","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1002\/art.38231","article-title":"Increased Risk of Complications Following Total Joint Arthroplasty in Patients With Rheumatoid Arthritis","volume":"66","author":"Ravi","year":"2014","journal-title":"Arthritis Rheumatol"},{"issue":"4","key":"10.1016\/j.rdc.2025.01.010_bib4","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1007\/s12325-018-0686-0","article-title":"Perioperative Management of Patients with Inflammatory Rheumatic Diseases Undergoing Major Orthopaedic Surgery: A Practical Overview","volume":"35","author":"Gualtierotti","year":"2018","journal-title":"Adv Ther"},{"issue":"12","key":"10.1016\/j.rdc.2025.01.010_bib5","doi-asserted-by":"crossref","first-page":"825","DOI":"10.7326\/M18-2217","article-title":"Risk of Biologics and Glucocorticoids in Patients With Rheumatoid Arthritis Undergoing Arthroplasty: A Cohort Study","volume":"170","author":"George","year":"2019","journal-title":"Ann Intern Med"},{"issue":"9","key":"10.1016\/j.rdc.2025.01.010_bib6","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1002\/acr.24893","article-title":"American College of Rheumatology\/American Association of Hip and Knee Surgeons Guideline for the Perioperative Management of Antirheumatic Medication in Patients With Rheumatic Diseases Undergoing Elective Total Hip or Total Knee Arthroplasty","volume":"74","author":"Goodman","year":"2022","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.rdc.2025.01.010_bib7","first-page":"16","article-title":"Methotrexate in rheumatoid arthritis: a quarter century of development","volume":"124","author":"Weinblatt","year":"2013","journal-title":"Trans Am Clin Climatological Assoc"},{"issue":"8","key":"10.1016\/j.rdc.2025.01.010_bib8","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1007\/s00296-009-1323-7","article-title":"Perioperative management of immunosuppression in rheumatic diseases--what to do?","volume":"30","author":"H\u00e4rle","year":"2010","journal-title":"Rheumatol Int"},{"issue":"5","key":"10.1016\/j.rdc.2025.01.010_bib9","first-page":"856","article-title":"A\u00a0systematic review on the optimum management of the use of methotrexate in rheumatoid arthritis patients in the perioperative period to minimize perioperative morbidity and maintain disease control","volume":"27","author":"Loza","year":"2009","journal-title":"Clin Exp Rheumatol"},{"issue":"3","key":"10.1016\/j.rdc.2025.01.010_bib10","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1006\/clim.1999.4777","article-title":"Mechanism of action for leflunomide in rheumatoid arthritis","volume":"93","author":"Fox","year":"1999","journal-title":"Clin Immunol (Orlando, Fla)"},{"issue":"12","key":"10.1016\/j.rdc.2025.01.010_bib11","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1007\/s00296-006-0138-z","article-title":"Leflunomide increases the risk of early healing complications in patients with rheumatoid arthritis undergoing elective orthopedic surgery","volume":"26","author":"Fuerst","year":"2006","journal-title":"Rheumatol Int"},{"issue":"12","key":"10.1016\/j.rdc.2025.01.010_bib12","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1002\/art.24060","article-title":"Incidence and risk factors of prosthetic joint infection after total hip or knee replacement in patients with rheumatoid arthritis","volume":"59","author":"Bongartz","year":"2008","journal-title":"Arthritis Rheum"},{"issue":"8","key":"10.1016\/j.rdc.2025.01.010_bib13","doi-asserted-by":"crossref","first-page":"748","DOI":"10.4065\/mcp.2011.0074","article-title":"Inflammatory bowel disease: perioperative pharmacological considerations","volume":"86","author":"Kumar","year":"2011","journal-title":"Mayo Clinic Proc"},{"issue":"5","key":"10.1016\/j.rdc.2025.01.010_bib14","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1111\/j.1572-0241.2004.04148.x","article-title":"Early postoperative complications are not increased in patients with Crohn\u2019s disease treated perioperatively with infliximab or immunosuppressive therapy","volume":"99","author":"Colombel","year":"2004","journal-title":"Am J Gastroenterol"},{"issue":"4","key":"10.1016\/j.rdc.2025.01.010_bib15","first-page":"689","article-title":"Risk factors for surgical site infections and other complications in elective surgery in patients with rheumatoid arthritis with special attention for anti-tumor necrosis factor: a large retrospective study","volume":"34","author":"den Broeder","year":"2007","journal-title":"The J Rheumatol"},{"issue":"1","key":"10.1016\/j.rdc.2025.01.010_bib16","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1186\/s12891-020-03459-z","article-title":"Anti-rheumatic treatment and prosthetic joint infection: an observational study in 494 elective hip and knee arthroplasties","volume":"21","author":"Borgas","year":"2020","journal-title":"BMC Musculoskelet Disord"},{"issue":"1","key":"10.1016\/j.rdc.2025.01.010_bib17","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1186\/s13075-019-1901-3","article-title":"Long-term experience with apremilast in patients with psoriatic arthritis: 5-year results from a PALACE 1-3 pooled analysis","volume":"21","author":"Kavanaugh","year":"2019","journal-title":"Arthritis Res Ther"},{"issue":"4s","key":"10.1016\/j.rdc.2025.01.010_bib18","doi-asserted-by":"crossref","first-page":"S71","DOI":"10.12788\/j.sder.2016.020","article-title":"New Therapies for Psoriasis","volume":"35","author":"Strober","year":"2016","journal-title":"Semin Cutan Med Surg"},{"issue":"5","key":"10.1016\/j.rdc.2025.01.010_bib19","doi-asserted-by":"crossref","first-page":"837","DOI":"10.3899\/jrheum.130683","article-title":"Safety and efficacy of tofacitinib, an oral janus kinase inhibitor, for the treatment of rheumatoid arthritis in open-label, longterm extension studies","volume":"41","author":"Wollenhaupt","year":"2014","journal-title":"The J Rheumatol"},{"issue":"21","key":"10.1016\/j.rdc.2025.01.010_bib20","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1182\/blood.2019002289","article-title":"Emapalumab for the treatment of relapsed\/refractory hemophagocytic lymphohistiocytosis","volume":"134","author":"Vallurupalli","year":"2019","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.rdc.2025.01.010_bib21","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1136\/ard-2022-223739","article-title":"Efficacy and safety of emapalumab in macrophage activation syndrome","volume":"82","author":"Benedetti","year":"2023","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.rdc.2025.01.010_bib22","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/s40265-018-1046-8","article-title":"Emapalumab: First Global Approval","volume":"79","author":"Al-Salama","year":"2019","journal-title":"Drugs"},{"key":"10.1016\/j.rdc.2025.01.010_bib23","doi-asserted-by":"crossref","first-page":"731798","DOI":"10.3389\/fphar.2021.731798","article-title":"PD-1\/PD-L1 Checkpoint Inhibitors in Tumor Immunotherapy","volume":"12","author":"Liu","year":"2021","journal-title":"Front Pharmacol"},{"issue":"3","key":"10.1016\/j.rdc.2025.01.010_bib24","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1007\/s11912-018-0671-4","article-title":"Incidence and Management of Immune-Related Adverse Events in Patients Undergoing Treatment with Immune Checkpoint Inhibitors","volume":"20","author":"Kottschade","year":"2018","journal-title":"Curr Oncol Rep"},{"issue":"5","key":"10.1016\/j.rdc.2025.01.010_bib25","first-page":"5671","article-title":"Immune-related adverse events during anticancer immunotherapy: Pathogenesis and management","volume":"14","author":"Stucci","year":"2017","journal-title":"Oncol Lett"},{"issue":"4","key":"10.1016\/j.rdc.2025.01.010_bib26","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1038\/nrendo.2016.205","article-title":"Cancer immunotherapy - immune checkpoint blockade and associated endocrinopathies","volume":"13","author":"Byun","year":"2017","journal-title":"Nat Rev Endocrinol"},{"issue":"10124","key":"10.1016\/j.rdc.2025.01.010_bib27","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1016\/S0140-6736(18)30533-6","article-title":"Increased reporting of fatal immune checkpoint inhibitor-associated myocarditis","volume":"391","author":"Moslehi","year":"2018","journal-title":"Lancet (London, England)"},{"issue":"8","key":"10.1016\/j.rdc.2025.01.010_bib28","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1634\/theoncologist.2018-0130","article-title":"Immune Checkpoint Inhibitor-Associated Myocarditis","volume":"23","author":"Ganatra","year":"2018","journal-title":"The oncologist"},{"issue":"2","key":"10.1016\/j.rdc.2025.01.010_bib29","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.chest.2017.04.177","article-title":"Incidence of Pneumonitis With Use of Programmed Death 1 and Programmed Death-Ligand 1 Inhibitors in Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis of Trials","volume":"152","author":"Khunger","year":"2017","journal-title":"Chest"},{"issue":"3","key":"10.1016\/j.rdc.2025.01.010_bib30","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.bja.2019.11.034","article-title":"Immune checkpoint inhibitors: a narrative review of considerations for the anaesthesiologist","volume":"124","author":"Lewis","year":"2020","journal-title":"Br J Anaesth"},{"issue":"2","key":"10.1016\/j.rdc.2025.01.010_bib31","doi-asserted-by":"crossref","first-page":"1","DOI":"10.15761\/GOS.1000157","article-title":"The safety of elective surgery with concurrent use of immunosuppresants","volume":"3","author":"Koons","year":"2017","journal-title":"Glob Surg"},{"key":"10.1016\/j.rdc.2025.01.010_bib32","first-page":"139","article-title":"Remicade(\u00ae) (infliximab): 20 years of contributions to science and medicine","volume":"13","author":"Melsheimer","year":"2019","journal-title":"Biologics : Targets Ther"},{"issue":"9","key":"10.1016\/j.rdc.2025.01.010_bib33","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1007\/s10067-007-0534-0","article-title":"Safety of etanercept therapy in rheumatoid patients undergoing surgery: preliminary report","volume":"26","author":"Corrao","year":"2007","journal-title":"Clin Rheumatol"},{"issue":"3","key":"10.1016\/j.rdc.2025.01.010_bib34","first-page":"220","article-title":"Preoperative Evaluation and Management of Patients Receiving Biologic Therapies","volume":"7","author":"Rezaieyazdi","year":"2019","journal-title":"The Arch bone Jt Surg"},{"issue":"3","key":"10.1016\/j.rdc.2025.01.010_bib35","first-page":"430","article-title":"Complication rates of 127 surgical procedures performed in rheumatic patients receiving tumor necrosis factor alpha blockers","volume":"25","author":"Ruyssen-Witrand","year":"2007","journal-title":"Clin Exp Rheumatol"},{"issue":"6","key":"10.1016\/j.rdc.2025.01.010_bib36","doi-asserted-by":"crossref","first-page":"386","DOI":"10.6061\/clinics\/2017(06)09","article-title":"Perioperative management of drugs commonly used in patients with rheumatic diseases: a review","volume":"72","author":"Franco","year":"2017","journal-title":"Clinics (Sao Paulo, Brazil)"},{"issue":"8","key":"10.1016\/j.rdc.2025.01.010_bib37","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1002\/art.23687","article-title":"Efficacy and safety of rilonacept (interleukin-1 Trap) in patients with cryopyrin-associated periodic syndromes: results from two sequential placebo-controlled studies","volume":"58","author":"Hoffman","year":"2008","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.rdc.2025.01.010_bib38","first-page":"39","article-title":"Hepatotoxicity of tocilizumab and anakinra in rheumatoid arthritis: management decisions","volume":"3","author":"Mahamid","year":"2011","journal-title":"Clin Pharmacol : Adv Appl"},{"issue":"3","key":"10.1016\/j.rdc.2025.01.010_bib39","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/S1074-7613(00)80334-9","article-title":"Role of IL-6 and its soluble receptor in induction of chemokines and leukocyte recruitment","volume":"6","author":"Romano","year":"1997","journal-title":"Immunity"},{"issue":"1","key":"10.1016\/j.rdc.2025.01.010_bib40","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1002\/jbmr.5650110113","article-title":"Interleukin-6 and soluble interleukin-6 receptors in the synovial fluids from rheumatoid arthritis patients are responsible for osteoclast-like cell formation","volume":"11","author":"Kotake","year":"1996","journal-title":"J\u00a0bone mineral Res : official J Am Soc Bone Mineral Res"},{"issue":"9","key":"10.1016\/j.rdc.2025.01.010_bib41","doi-asserted-by":"crossref","first-page":"2817","DOI":"10.1002\/art.22033","article-title":"Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate","volume":"54","author":"Maini","year":"2006","journal-title":"Arthritis Rheum"},{"issue":"16","key":"10.1016\/j.rdc.2025.01.010_bib42","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1056\/NEJMoa2100433","article-title":"Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19","volume":"384","year":"2021","journal-title":"New Engl J Med"},{"issue":"2","key":"10.1016\/j.rdc.2025.01.010_bib43","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1097\/PPO.0000000000000035","article-title":"Managing cytokine release syndrome associated with novel T\u00a0cell-engaging therapies","volume":"20","author":"Maude","year":"2014","journal-title":"Cancer J (Sudbury, Mass)"},{"issue":"3","key":"10.1016\/j.rdc.2025.01.010_bib44","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1136\/annrheumdis-2016-209773","article-title":"Risk for lower intestinal perforations in patients with rheumatoid arthritis treated with tocilizumab in comparison to treatment with other biologic or conventional synthetic DMARDs","volume":"76","author":"Strangfeld","year":"2017","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"10.1016\/j.rdc.2025.01.010_bib45","first-page":"541","article-title":"Effect of tocilizumab on neutrophils in adult patients with rheumatoid arthritis: pooled analysis of data from phase 3 and 4 clinical trials","volume":"56","author":"Moots","year":"2016","journal-title":"Rheumatology"},{"issue":"7","key":"10.1016\/j.rdc.2025.01.010_bib46","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1093\/rheumatology\/kes397","article-title":"Severe hepatitis associated with tocilizumab in a patient with rheumatoid arthritis","volume":"52","author":"Alfreijat","year":"2013","journal-title":"Rheumatology"},{"issue":"5","key":"10.1016\/j.rdc.2025.01.010_bib47","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1007\/s00296-019-04456-9","article-title":"Tocilizumab-induced anaphylaxis in patients with adult-onset Still\u2019s disease and systemic juvenile idiopathic arthritis: a case-based review","volume":"40","author":"Park","year":"2020","journal-title":"Rheumatol Int"},{"issue":"4","key":"10.1016\/j.rdc.2025.01.010_bib48","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1136\/annrheumdis-2018-214367","article-title":"Risk of serious infections in tocilizumab versus other biologic drugs in patients with rheumatoid arthritis: a multidatabase cohort study","volume":"78","author":"Pawar","year":"2019","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"10.1016\/j.rdc.2025.01.010_bib49","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1016\/j.jbspin.2008.02.009","article-title":"Rituximab: A new therapeutic alternative in rheumatoid arthritis","volume":"75","author":"Sibilia","year":"2008","journal-title":"Joint Bone Spine"},{"issue":"2 Suppl 2","key":"10.1016\/j.rdc.2025.01.010_bib50","doi-asserted-by":"crossref","first-page":"S314","DOI":"10.1016\/j.jaci.2009.08.018","article-title":"Immunomodulator therapy: monoclonal antibodies, fusion proteins, cytokines, and immunoglobulins","volume":"125","author":"Lee","year":"2010","journal-title":"The J Allergy Clin Immunol"},{"issue":"6","key":"10.1016\/j.rdc.2025.01.010_bib51","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1136\/ard.2010.144998","article-title":"Updated consensus statement on the use of rituximab in patients with rheumatoid arthritis","volume":"70","author":"Buch","year":"2011","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"10.1016\/j.rdc.2025.01.010_bib52","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1002\/art.21778","article-title":"The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial","volume":"54","author":"Emery","year":"2006","journal-title":"Arthritis Rheum"},{"issue":"9","key":"10.1016\/j.rdc.2025.01.010_bib53","doi-asserted-by":"crossref","first-page":"2793","DOI":"10.1002\/art.22025","article-title":"Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks","volume":"54","author":"Cohen","year":"2006","journal-title":"Arthritis Rheum"},{"issue":"1","key":"10.1016\/j.rdc.2025.01.010_bib54","doi-asserted-by":"crossref","first-page":"72","DOI":"10.5217\/ir.2020.00117","article-title":"Vedolizumab does not increase perioperative surgical complications in patients with inflammatory bowel disease, cohort study","volume":"20","author":"Poylin","year":"2022","journal-title":"Intest Res"},{"issue":"13","key":"10.1016\/j.rdc.2025.01.010_bib55","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.2174\/1389450120666190325130142","article-title":"Vedolizumab in the Perioperative Management of Inflammatory Bowel Disease","volume":"20","author":"Lightner","year":"2019","journal-title":"Curr Drug Targets"},{"issue":"5","key":"10.1016\/j.rdc.2025.01.010_bib56","doi-asserted-by":"crossref","first-page":"550","DOI":"10.4103\/0019-5154.190107","article-title":"Belimumab in systemic lupus erythematosus","volume":"61","author":"Srivastava","year":"2016","journal-title":"Indian J Dermatol"},{"issue":"11","key":"10.1016\/j.rdc.2025.01.010_bib57","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1007\/s40265-017-0775-4","article-title":"Abatacept: A Review in Rheumatoid Arthritis","volume":"77","author":"Blair","year":"2017","journal-title":"Drugs"},{"issue":"3","key":"10.1016\/j.rdc.2025.01.010_bib58","doi-asserted-by":"crossref","first-page":"544","DOI":"10.3109\/14397595.2013.874758","article-title":"Abatacept management during the perioperative period in patients with rheumatoid arthritis: report on eight orthopaedic procedures","volume":"24","author":"Nishida","year":"2014","journal-title":"Mod Rheumatol"},{"issue":"9","key":"10.1016\/j.rdc.2025.01.010_bib59","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1002\/acr.23843","article-title":"Timing of Abatacept Before Elective Arthroplasty and Risk of Postoperative Outcomes","volume":"71","author":"George","year":"2019","journal-title":"Arthritis Care Res"}],"container-title":["Rheumatic Disease Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889857X25000109?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889857X25000109?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,19]],"date-time":"2025-06-19T11:16:13Z","timestamp":1750331773000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889857X25000109"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":59,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["S0889857X25000109"],"URL":"https:\/\/doi.org\/10.1016\/j.rdc.2025.01.010","relation":{},"ISSN":["0889-857X"],"issn-type":[{"type":"print","value":"0889-857X"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Newer Immunosuppressants for Rheumatologic Disease","name":"articletitle","label":"Article Title"},{"value":"Rheumatic Disease Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rdc.2025.01.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}